Clinical Trials
Find information about clinical trials for ADC Therapeutics products.
| Trial Title | Status | Phase |
|
|---|---|---|---|
| A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | Completed | Phase 1 | NCT02669017 |
| A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Active, Not recruiting | Phase 2 | NCT03589469 |
| A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | Recruiting | Phase 1/2 | NCT03684694 |
| A Phase 1 Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Durvalumab in Patients With Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma | Active, Not recruiting | Phase 1 | NCT03685344 |
| A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Recruiting | Phase 3 | NCT04384484 |
| Trial Title | Status | Phase |
|
|---|---|---|---|
| Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Recruiting | Phase 1 | NCT03621982 |
LOTIS Video
Learn about the LOTIS clinical development program (3:00)
Watch videoLOTIS Digital Leaflet
